News Psilocybin reduces symptoms in treatment resistant depression, trial results show BMJ 2022; 379 doi: https://doi.org/10.1136/bmj.o2623 (Published 02 November 2022) Cite this as: BMJ 2022;379:o2623 Article Related content Metrics Responses Peer review Related articles News Australia’s approval of MDMA and psilocybin for PTSD and depression is premature, say critics Published: 11 July 2023; BMJ 382 doi:10.1136/bmj.p1599 See more Valproate prescribing rules will tighten from January, says MHRA BMJ November 29, 2023, 383 p2836; DOI: https://doi.org/10.1136/bmj.p2836 Scarlett McNally: Rethinking ageing can help the NHS recover BMJ November 28, 2023, 383 p2775; DOI: https://doi.org/10.1136/bmj.p2775 Helen Salisbury: Training in the medical model BMJ November 28, 2023, 383 p2793; DOI: https://doi.org/10.1136/bmj.p2793 England’s GP leader calls for end to “ridiculous” bureaucracy BMJ November 28, 2023, 383 p2813; DOI: https://doi.org/10.1136/bmj.p2813 Rise in people found dead and decomposed suggests breakdown of support networks, say researchers BMJ November 24, 2023, 383 p2782; DOI: https://doi.org/10.1136/bmj.p2782
